Cipher Pharmaceuticals (CPH) Shares Down 3.9%

Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) shares fell 3.9% during trading on Thursday . The stock traded as low as C$3.80 and last traded at C$3.95. 6,480 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 11,106 shares. The stock had previously closed at C$4.11.

Separately, TD Securities decreased their price objective on Cipher Pharmaceuticals from C$6.50 to C$5.00 and set a “hold” rating on the stock in a research note on Tuesday, November 7th.

The firm has a market cap of $109.90, a P/E ratio of -17.18 and a beta of 1.26.

COPYRIGHT VIOLATION WARNING: This report was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2018/02/10/cipher-pharmaceuticals-cph-shares-down-3-9.html.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply